Lack of benefit of intravenous immune globulin in a murine model of group A streptococcal necrotizing fasciitis

Journal of Infectious Diseases

Volumn 181, Issue 1, 2000, Pages 230-234

  Patel, Robin ^a   Rouse, Mark S ^a   Florez, Monica V ^a   Piper, Kerryl E ^a   Cockerill, Franklin R ^a   Wilson, Walter R ^a   Steckelberg, James M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; IMMUNOGLOBULIN G; PENICILLIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COUNT; DRUG EFFICACY; MOUSE; NECROTIZING FASCIITIS; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; CLINDAMYCIN; DRUG THERAPY, COMBINATION; FASCIITIS, NECROTIZING; IMMUNOGLOBULINS, INTRAVENOUS; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; PENICILLINS; STREPTOCOCCUS PYOGENES;

EID: 0033955010     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315198     Document Type: Article

References (28)

1. 1. Cockerill FR, MacDonald KL, Thompson RL, et al. An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children. JAMA 1997;277:38-43.
2. 2. Stevens DL, Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988;158:23-8.
3. 3. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissue. New Engl J Med 1996;334:240-5.
4. 4. Stevens DL, Yan S, Bryant AE. Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J Infect Dis 1993;167:1401-5.
5. 5. Stevens DL, Bryant AE, Hackett SP. Antibiotic effects on bacterial viability, toxin production, and host response. Clin Infect Dis 1995;20 (Suppl. 2): 5154-7.
6. 6. Yan S, Bohach GA, Stevens DL. Persistent acylation of high-molecular-weight penicillin-binding proteins by penicillin induces the postantibiotic effect in Streptococcus pyogenes. J Infect Dis 1994;170:609-14.
7. 7. Betriu C, Sanchez A, Gomez M, Cruceyra A, Picazo JJ. Antibiotic susceptibility of group A streptococci: a 6-year follow-up study Antimicrob Agents Chemother 1993;37:1717-9.
8. 8. Holm SE, Norrby A, Bergholm AM, Norgren M. Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. J Infect Dis 1992;166:31-7.
9. 9. Norrby-Teglund A, Pauksens K, Holm SE, Norgren M. Relation between low capacity of human sera to inhibit streptococcal mitogens and serious manifestation of disease. J Infect Dis 1994;170:585-91.
10. 10. Basma H, Norrby-Teglund A, McGeer A, et al. Opsonic antibodies to the surface M protein of group A streptococci in pooled normal immunoglobulins (IVIG): potential impact on the clinical efficacy of IVIG therapy for severe invasive group A streptococcal infections. Infect Immun 1998;66:2279-83.
11. 11. Norrby-Teglund A, Kaul R, Low DE, et al. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol 1996;156:3057-64.
12. 12. Perez CM, Kubak BM, Cryer HG, Salehmugodam S, Vespa P, Farmer D. Adjunctive treatment of streptococcal toxic shock syndrome using intravenous immunoglobulin: case report and review. Am J Med 1997;102: 111-3.
13. 13. Lamothe F, D'Amico P, Ghosn P, Tremblay C, Braidy J, Patenaude JV. Clinical usefulness of intravenous human immunoglobulins in invasive group A streptococcal infections: case report and review. Clin Infect Dis 1995;21:1469-70.
14. 14. Yong JM. Necrotising fasciitis. Lancet 1994;343:4.
15. 15. Barry W, Hudgins L, Donta ST, Pesanti EL. Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA 1992;267:3315-6.
16. 16. Mahieu LM, Holm SE, Goossens HJ, Van Acker KJ. Congenital streptococcal toxic shock syndrome with absence of antibodies against streptococcal pyrogenic exotoxins. J Pediatr 1995:127:987-9.
17. 17. Nadal D, Lauener RP, Braegger CP, et al. T cell activation and cytokine release in streptococcal toxic shock-like syndrome. J Pediatr 1993;122: 727-9.
18. 18. Chiu CH, Ou JT, Chang KS, Lin TY. Successful treatment of severe streptococcal toxic shock syndrome with a combination of intravenous immunoglobulin, dexamethasone and antibiotics. Infection 1997;25:47-8.
19. 19. Stegmayr B, Bjorck S, Holm S, Nisell J, Rydvall A, Settergren B. Septic shock induced by group A streptococcal infection: clinical and therapeutic aspects. Scand J Infect Dis 1992;24:589-97.
20. 20. Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy in streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis 1999;28:800-7.
21. 21. Stevens DL. Rationale for the use of intravenous gamma globulin in the treatment of streptococcal toxic shock syndrome. Clin Infect Dis 1998; 26:639-41.
22. 22. Cockerill FR, Thompson RL, Musser JM, et al. Molecular, serological, and clinical features of 16 consecutive cases of invasive streptococcal disease. Southeastern Minnesota Streptococcal Working Group. Clin Infect Dis 1998;26:1448-58.
23. 23. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. M7-A4. Villanova, PA: National Committee for Clinical Laboratory Standards, 1997.
24. 24. Acred P. The Selbie of Thigh Lesion Test. In: Zak O, Sande M, eds. Experimental models in antimicrobial chemotherapy, vol. 1. London: Academic Press, 1986:109-22.
25. 25. Klassen M, Edberg SC. Measurement of antibiotics in human body fluids: techniques and significance. In: Lorian V. ed. Antibiotics in laboratory medicine. 4th ed. Baltimore: Williams and Wilkins, 1996:230-40.
26. 26. Dinges MM, Schlievert PM. Comparison of mouse and rabbit models of human toxic shock syndrome. Presented at the 97th general meeting of the American Society for Microbiology (Miami Beach), May 1997. Abstract B-406.
27. 27. Norrby-Teglund A, Basma H, Andersson J, McGeer A, Low DE, Kotb M. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clin Infect Dis 1998;26:631-8.
28. 28. Stevens DL, Madara-Kelly KJ, Richards DM. In vitro antimicrobial effects of various combinations of penicillin and clindamycin against four strains of Streptococcus pyogenes. Antimicrob Agents Chemother 1998;42: 1266-8.